EntryPoint Capital’s GSK GSK Stock Holding History

EntryPoint Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	+6,632	New	+$351K	0.08%	484

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

EntryPoint Capital's GSK Position: Q2 2026 in Review

EntryPoint Capital opened a new position in GSK (GSK) in Q2 2026: 6,632 shares worth $348K. The stake represents 0.08% of the portfolio and ranks #484 among its holdings.

1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

EntryPoint Capital held 6,632 shares of GSK worth $348K as of Q2 2026.
GSK was a new EntryPoint Capital position in Q2 2026.
GSK made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #484 holding.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.